We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$6.41B
AUM Growth
-$960M
Cap. Flow
-$525M
Cap. Flow %
-8.19%
Top 10 Hldgs %
70.89%
Holding
50
New
7
Increased
8
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$39.7M
2
GPCR icon
Structure Therapeutics
GPCR
+$32.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$29.7M
4
AKRO
Akero Therapeutics
AKRO
+$25.9M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$23.9M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$317M
2
ARGX icon
argenx
ARGX
+$129M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$102M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
NUVL
Nuvalent
NUVL
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$28.1M 0.44%
+555,555
New +$25.9M
KURA icon
27
Kura Oncology
KURA
$1.01B
$27.2M 0.42%
2,980,000
-125,000
-4% -$1.27M
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$374M
$25.6M 0.4%
+1,250,000
New +$22.7M
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$25.4M 0.4%
3,150,000
– –
TNGX icon
30
Tango Therapeutics
TNGX
$4.03B
$25M 0.39%
2,222,222
+582,222
+36% +$3.55M
GLUE icon
31
Monte Rosa Therapeutics
GLUE
$1.11B
$21.7M 0.34%
4,535,000
– –
CERE
32
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$20.9M 0.33%
+955,555
New +$23.9M
PMVP icon
33
PMV Pharmaceuticals
PMVP
$72.7M
$18.4M 0.29%
3,000,000
-60,000
-2% -$413K
RNAM
34
DELISTED
Avidity Biosciences
RNAM
$16M 0.25%
2,510,000
– –
ARWR icon
35
Arrowhead Research
ARWR
$9.98B
$15.2M 0.24%
565,000
+207,597
+58% +$6.36M
WHWK
36
Whitehawk Therapeutics
WHWK
$233M
$13.8M 0.22%
2,849,402
– –
TSHA icon
37
Taysha Gene Therapies
TSHA
$1.65B
$12.4M 0.19%
+3,925,000
New +$7.33M
VRCA icon
38
Verrica Pharmaceuticals
VRCA
$78.7M
$11.5M 0.18%
295,406
– –
MRUS
39
DELISTED
Merus
MRUS
$10.5M 0.16%
+444,444
New +$10.8M
FENC icon
40
Fennec Pharmaceuticals
FENC
$373M
$9.01M 0.14%
1,200,000
– –
IMA
41
ImageneBio Inc
IMA
$55.8M
$7.1M 0.11%
136,667
– –
MCRB icon
42
Seres Therapeutics
MCRB
$46.2M
$5.95M 0.09%
125,000
– –
IOBT
43
DELISTED
IO Biotech
IOBT
$2.84M 0.04%
2,055,883
– –
TRML
44
DELISTED
Tourmaline Bio
TRML
$1.41M 0.02%
50,000
– –
QQQ icon
45
PUT
Invesco QQQ Trust
QQQ
$474B
$1.22M 0.02%
+500,000
New +$185M
SYRE icon
46
Spyre Therapeutics
SYRE
$8.02B
$140K ﹤0.01%
11,458
– –
DSGN icon
47
Design Therapeutics
DSGN
$765M
– –
-3,500,000
Closed -$22.1M
MRSN
48
DELISTED
Mersana Therapeutics
MRSN
– –
-255,000
Closed -$21M
DICE
49
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-2,199,342
Closed -$102M
ISEE
50
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-8,050,000
Closed -$317M
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Avoro Capital Advisors held 50 positions worth $6.41B, down 13% from $7.37B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Avoro Capital Advisors withdrew a net $525M in Q3 2023, closing 4 positions and reducing 12 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $317M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avoro Capital Advisors opened a new position in Structure Therapeutics worth $50.4M.

  • Avoro Capital Advisors's largest Q3 2023 buy was Structure Therapeutics: 1,000,000 shares worth $50.4M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $39.7M increase.
  • Avoro Capital Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $129M.
  • Avoro Capital Advisors fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $317M.
  • Avoro Capital Advisors's ten largest holdings make up 71% of its $6.41B portfolio in Q3 2023.
  • Avoro Capital Advisors opened 7 new positions and closed 4 in Q3 2023.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $6.41B.

Based on Avoro Capital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.